Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers

Megan M Bernath1, Sudeepa Bhattacharyya1, Kwangsik Nho1

  • 1From the Department of Radiology and Imaging Sciences (M.M.B., K.N., S.L.R., T.J., A.J.S.), Center for Neuroimaging, Indiana Alzheimer Disease Center (M.M.B., K.N., S.L.R., T.J., A.J.S.), Medical and Molecular Genetics Department (M.M.B., T.J., A.J.S.), and Medical Scientist Training Program (M.M.B.), Indiana University School of Medicine, Indianapolis; Department of Pediatrics (S.B.), University of Arkansas for Medical Sciences, Little Rock; Department of Environmental Medicine and Public Health (D.K.B.), Icahn School of Medicine at Mt Sinai, New York; NIH-West Coast Metabolomics Center (D.K.B., O.F.), University of California, Davis; Rosa & Co LLC (R.B.), San Carlos, CA; Institute of Bioinformatics and Systems Biology (M.A.), Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany; Department of Pathology & Laboratory Medicine (J.Q.T., L.M.S.), University of Pennsylvania, Philadelphia; Department of Radiology (M.W.W.), Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center/University of California San Francisco; and Department of Psychiatry and Behavioral Sciences (M.A., P.M.D., R.K.-D.), Duke Institute of Brain Sciences (R.K.-D.), and Department of Medicine (R.K.-D.), Duke University, Durham, NC.

Neurology
|May 3, 2020
PubMed
Abstract